Newsfeeds Archive - Page 483 of 19074

1 minute read

News

Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform

May 30, 4:02 PM

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform

ADAP

3 minute read

Analyst Ratings

A Closer Look at 7 Analyst Recommendations For American Tower

By Benzinga Insights

May 30, 4:01 PM

American Tower (NYSE:AMT) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from…

AMT

3 minute read

Analyst Ratings

What Analysts Are Saying About National Health Investors Stock

By Benzinga Insights

May 30, 4:01 PM

In the latest quarter, 4 analysts provided ratings for National Health Investors (NYSE:NHI), showcasing a mix of bullish…

NHI

3 minute read

Behind the Scenes of Spotify Technology’s Latest Options Trends

By Benzinga Insights

May 30, 4:01 PM

Deep-pocketed investors have adopted a bullish approach towards Spotify Technology (NYSE:SPOT), and it’s something market players shouldn’t ignore.…

SPOT

3 minute read

Analyst Ratings

12 Analysts Assess eBay: What You Need To Know

By Benzinga Insights

May 30, 4:01 PM

In the latest quarter, 12 analysts provided ratings for eBay (NASDAQ:EBAY), showcasing a mix of bullish and bearish…

EBAY

3 minute read

Smart Money Is Betting Big In MRK Options

By Benzinga Insights

May 30, 4:01 PM

Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE:MRK).…

MRK

3 minute read

Analyst Ratings

Deep Dive Into Ciena Stock: Analyst Perspectives (8 Ratings)

By Benzinga Insights

May 30, 4:01 PM

8 analysts have expressed a variety of opinions on Ciena (NYSE:CIEN) over the past quarter, offering a diverse…

CIEN

1 minute read

Ultragenyx Announces Top-Line Results From Phase 3 Study of DTX401 Gene Therapy For Glycogen Storage Disease Type Ia

By Benzinga Newsdesk

May 30, 4:00 PM

Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m.

RARE